RU2008105663A - Способ лечения рака (варианты) - Google Patents
Способ лечения рака (варианты) Download PDFInfo
- Publication number
- RU2008105663A RU2008105663A RU2008105663/14A RU2008105663A RU2008105663A RU 2008105663 A RU2008105663 A RU 2008105663A RU 2008105663/14 A RU2008105663/14 A RU 2008105663/14A RU 2008105663 A RU2008105663 A RU 2008105663A RU 2008105663 A RU2008105663 A RU 2008105663A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- substituents
- group
- nitro
- nitro group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 19
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 12
- 201000011510 cancer Diseases 0.000 title claims abstract 7
- 125000001424 substituent group Chemical group 0.000 claims abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 13
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 12
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- -1 hydroxy, amino, nitro, iodo Chemical group 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000001246 bromo group Chemical group Br* 0.000 claims abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 6
- 229910052740 iodine Inorganic materials 0.000 claims abstract 6
- 239000011630 iodine Substances 0.000 claims abstract 6
- 239000002207 metabolite Substances 0.000 claims abstract 6
- 229940002612 prodrug Drugs 0.000 claims abstract 6
- 239000000651 prodrug Substances 0.000 claims abstract 6
- 239000012453 solvate Substances 0.000 claims abstract 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 3
- 201000005202 lung cancer Diseases 0.000 claims abstract 3
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract 2
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 2
- 206010038389 Renal cancer Diseases 0.000 claims abstract 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract 2
- 201000007455 central nervous system cancer Diseases 0.000 claims abstract 2
- 201000010881 cervical cancer Diseases 0.000 claims abstract 2
- 208000024519 eye neoplasm Diseases 0.000 claims abstract 2
- 201000010175 gallbladder cancer Diseases 0.000 claims abstract 2
- 201000010982 kidney cancer Diseases 0.000 claims abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 2
- 201000008106 ocular cancer Diseases 0.000 claims abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 2
- 201000002510 thyroid cancer Diseases 0.000 claims abstract 2
- 210000005075 mammary gland Anatomy 0.000 claims 7
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims 1
- 210000000277 pancreatic duct Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000005555 sulfoximide group Chemical group 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- YEUGEQUFPMJGCD-UHFFFAOYSA-N Cc(ccc(C(N)=O)c1)c1[N+]([O-])=O Chemical compound Cc(ccc(C(N)=O)c1)c1[N+]([O-])=O YEUGEQUFPMJGCD-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1c(*)c(OC(C=C2)=O)c2c(*)c1* Chemical compound Cc1c(*)c(OC(C=C2)=O)c2c(*)c1* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Способ лечения рака, заключающийся во введении субъекту, нуждающемуся в этом, эффективного количества композиции, содержащей соединение по формуле (Ia) ! ! где R1, R2, R3, R4 и R5, независимо друг от друга, выбраны из группы, включающей: водород, гидрокси-, амино-, нитро-, йод-, бром-, фтор-, хлор- (С1-С6)алкил, (С1-С6)алкокси, (С3-С7)циклоалкил, и фенил, при этом, по крайней мере два радикала из пяти R1, R2, R3, R4 и R5 заместителей всегда представляют собой водород, по крайней мере один из пяти заместителей представляет собой нитро-группу, по крайней мере, один из заместителей, прикрепленных к нитро-группе, представляет собой йод; а также его фармацевтически доступные соли, сольваты, изомеры, таутомеры, метаболиты, аналоги или пролекарства, ! при этом способ предназначен для лечения таких раковых заболеваний, как рак яичников, рак эндометрия, рак шейки матки, рак поджелудочной железы, рак желчного пузыря, рак тканей глаза, рак центральной нервной системы, рак почки, рак щитовидной железы и рак легких. ! 2. Способ лечения рака, заключающийся во введении субъекту, нуждающемуся в этом, эффективного количества композиции, содержащей соединение по формуле (Ia) ! ! где R1, R2, R3, R4 и R5, независимо друг от друга, выбраны из группы, включающей: водород, гидрокси-, амино-, нитро-, йод-, бром-, фтор-, хлор- (С1-С6)алкил, (С1-С6)алкокси, (С3-С7)циклоалкил, и фенил, при этом, по крайней мере два радикала из пяти R1, R2, R3, R4 и R5 заместителей всегда представляют собой водород, по крайней мере один из пяти заместителей представляет собой нитро-группу, по крайней мере, один из заместителей, прикрепленных к нитро-группе, представляет собой йод; а также его фармацевтически доступные соли, с
Claims (11)
1. Способ лечения рака, заключающийся во введении субъекту, нуждающемуся в этом, эффективного количества композиции, содержащей соединение по формуле (Ia)
где R1, R2, R3, R4 и R5, независимо друг от друга, выбраны из группы, включающей: водород, гидрокси-, амино-, нитро-, йод-, бром-, фтор-, хлор- (С1-С6)алкил, (С1-С6)алкокси, (С3-С7)циклоалкил, и фенил, при этом, по крайней мере два радикала из пяти R1, R2, R3, R4 и R5 заместителей всегда представляют собой водород, по крайней мере один из пяти заместителей представляет собой нитро-группу, по крайней мере, один из заместителей, прикрепленных к нитро-группе, представляет собой йод; а также его фармацевтически доступные соли, сольваты, изомеры, таутомеры, метаболиты, аналоги или пролекарства,
при этом способ предназначен для лечения таких раковых заболеваний, как рак яичников, рак эндометрия, рак шейки матки, рак поджелудочной железы, рак желчного пузыря, рак тканей глаза, рак центральной нервной системы, рак почки, рак щитовидной железы и рак легких.
2. Способ лечения рака, заключающийся во введении субъекту, нуждающемуся в этом, эффективного количества композиции, содержащей соединение по формуле (Ia)
где R1, R2, R3, R4 и R5, независимо друг от друга, выбраны из группы, включающей: водород, гидрокси-, амино-, нитро-, йод-, бром-, фтор-, хлор- (С1-С6)алкил, (С1-С6)алкокси, (С3-С7)циклоалкил, и фенил, при этом, по крайней мере два радикала из пяти R1, R2, R3, R4 и R5 заместителей всегда представляют собой водород, по крайней мере один из пяти заместителей представляет собой нитро-группу, по крайней мере, один из заместителей, прикрепленных к нитро-группе, представляет собой йод; а также его фармацевтически доступные соли, сольваты, изомеры, таутомеры, метаболиты, аналоги или пролекарства,
при этом способ предназначен для лечения таких раковых заболеваний, как карцинома протоков молочной железы, инфильтрирующая карцинома молочной железы лобулярного типа, внутрипротоковая карцинома молочной железы, музинозная карцинома молочной железы, промиелоцитарный лейкоз периферической крови, аденокарцинома яичников, аденокарцинома яичников с прорастанием в брюшную полость, аденокарцинома предстательной железы, переходноклеточная карцинома желчного пузыря, эпителиоидная карцинома панкреатического протока, аденокарцинома панкреатического протока, аденокарцинома эпителия шейки матки и рак легких.
3. Способ лечения рака, заключающийся во введении субъекту, нуждающемуся в этом, эффективного количества композиции, содержащей соединение по формуле (Ia)
где R1, R2, R3, R4 и R5, независимо друг от друга, выбраны из группы, включающей: водород, гидрокси-, амино-, нитро-, йод-, бром-, фтор-, хлор- (С1-С6)алкил, (C1-С6)алкокси, (С3-С7)циклоалкил, и фенил, при этом, по крайней мере два радикала из пяти R1, R2, R3, R4 и R5 заместителей всегда представляют собой водород, по крайней мере один из пяти заместителей представляет собой нитро-группу, по крайней мере, один из заместителей, прикрепленных к нитро-группе, представляет собой йод; а также его фармацевтически доступные соли, сольваты, изомеры, таутомеры, метаболиты, аналоги или пролекарства,
при этом способ предназначен для лечения таких раковых заболеваний, как инфильтрирующая карцинома молочной железы лобулярного типа, внутрипротоковая карцинома молочной железы и музинозная карцинома молочной железы.
4. Способ лечения рака, заключающийся во введении субъекту, нуждающемуся в этом, эффективного количества композиции, содержащей соединение по формуле (Ia)
где R1, R2, R3, R4 и R5, независимо друг от друга, выбраны из группы, включающей: водород, гидрокси-, амино-, нитро-, йод-, бром-, фтор-, хлор- (С1-С6)алкил, (C1-С6)алкокси, (С3-С7)циклоалкил, и фенил, при этом, по крайней мере два радикала из пяти R1, R2, R3, R4 и R5 заместителей всегда представляют собой водород, по крайней мере один из пяти заместителей представляет собой нитро-группу, по крайней мере, один из заместителей, прикрепленных к нитро-группе, представляет собой йод; а также его фармацевтически доступные соли, сольваты, изомеры, таутомеры, метаболиты, аналоги или пролекарства,
при этом способ предназначен для лечения таких раковых заболеваний, как рак толстого кишечника, рак предстательной железы, рак печени, лейкоз, глиома и меланома.
5. Способ по любому из пп.1-3 или 4, дополнительно включающий применение хирургического вмешательства, лучевой терапии, химиотерапии, генной терапии, иммунотерапии или их комбинаций.
6. Способ по любому из пп.1-3 или 4, дополнительно включающий введение эффективного количества бутионина сульфоксимина.
7. Способ по любому из пп.1-3 или 4, при котором указанное соединение имеет формулу
8. Способ по любому из пп.1-3 или 4, при котором композиция вводится внутривенно.
9. Способ по любому из пп.1-3 или 4, при котором указанное соединение ингибирует молекулу поли-АДФ-рибозополимеразу (PARP) в организме указанного субъекта.
10. Способ по любому из пп.1-3 или 4, при котором происходит апоптоз опухолевых клеток, нарушение клеточного цикла опухолевых клеток и/или некроз опухоли у указанного субъекта.
11. Способ по любому из пп.1-3 или 4, который дополнительно включает введение эффективного количества соединения бензопирона формулы (II)
где R1, R2, R3 и R4 независимо друг от друга, выбраны из группы, включающей Н, галоген, факультативно замещенный гидрокси, факультативно замещенный амин, факультативно замещенный низший алкил, факультативно замещенный фенил, факультативно замещенный С4-С10 гетероарил или факультативно замещенный С3-C8 циклоалкил или его соли, сольвата, изомера, таутомера, метаболита или пролекарства.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70044605P | 2005-07-18 | 2005-07-18 | |
| US60/700,446 | 2005-07-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011152491/15A Division RU2011152491A (ru) | 2005-07-18 | 2011-12-22 | Способ лечения рака (варианты) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008105663A true RU2008105663A (ru) | 2009-08-27 |
| RU2447889C2 RU2447889C2 (ru) | 2012-04-20 |
Family
ID=37669518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008105663/15A RU2447889C2 (ru) | 2005-07-18 | 2006-07-18 | Способ лечения рака (варианты) |
| RU2011152491/15A RU2011152491A (ru) | 2005-07-18 | 2011-12-22 | Способ лечения рака (варианты) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011152491/15A RU2011152491A (ru) | 2005-07-18 | 2011-12-22 | Способ лечения рака (варианты) |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7405227B2 (ru) |
| EP (1) | EP1906948A4 (ru) |
| JP (2) | JP5177429B2 (ru) |
| KR (2) | KR20130028149A (ru) |
| CN (2) | CN101242822B (ru) |
| BR (1) | BRPI0613783A2 (ru) |
| CA (1) | CA2615374A1 (ru) |
| IL (1) | IL188746A0 (ru) |
| NO (1) | NO20080785L (ru) |
| NZ (2) | NZ587586A (ru) |
| RU (2) | RU2447889C2 (ru) |
| SG (1) | SG164368A1 (ru) |
| WO (1) | WO2007011962A2 (ru) |
| ZA (1) | ZA200800907B (ru) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2762111C1 (ru) * | 2010-08-24 | 2021-12-15 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Соединения для лечения рака |
| US11465987B2 (en) | 2010-03-01 | 2022-10-11 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| US12187720B2 (en) | 2010-03-01 | 2025-01-07 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7961081B2 (en) * | 2003-05-22 | 2011-06-14 | John Tomlienovic | Anti-theft system and method |
| BRPI0611814A2 (pt) * | 2005-06-10 | 2008-12-09 | Bipar Sciences Inc | moduladores parp e tratamento de cÂnceres |
| NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| US20080076778A1 (en) * | 2006-09-05 | 2008-03-27 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| EP2061479A4 (en) * | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
| HRP20120960T1 (hr) * | 2007-01-16 | 2012-12-31 | Bipar Sciences, Inc. | Formulacije za lijeäśenje raka |
| WO2008112129A2 (en) * | 2007-03-09 | 2008-09-18 | Geron Corporation | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors |
| US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| AU2008298592A1 (en) | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| CN101903025A (zh) * | 2007-10-19 | 2010-12-01 | 彼帕科学公司 | 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物 |
| US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2705537A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20090149397A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| WO2009137649A2 (en) * | 2008-05-07 | 2009-11-12 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
| ES2566338T3 (es) * | 2008-10-17 | 2016-04-12 | Geron Corporation | Método para identificación de la sensibilidad de un paciente a la terapia de inhibición de la telomerasa |
| US20110311651A1 (en) * | 2008-12-10 | 2011-12-22 | Sloan-Kettering Institute For Cancer Research | Cardenolides for the treatment of ocular cancer |
| WO2010081778A1 (en) * | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
| MX2011008221A (es) * | 2009-02-04 | 2011-08-17 | Bipar Sciences Inc | Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno. |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US8663210B2 (en) * | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
| AU2010212513B2 (en) * | 2009-10-02 | 2016-08-25 | Monash University | Ectopic pregnancy treatment |
| US20140303109A1 (en) * | 2010-03-25 | 2014-10-09 | Fazlul H. Sarkar | Novel Analogs of Curcumin and Methods of Use |
| WO2011130692A2 (en) * | 2010-04-16 | 2011-10-20 | Colby Pharmaceutical Company | Androgen induced oxidative stress inhibitors |
| US20120107300A1 (en) * | 2010-11-01 | 2012-05-03 | Jeffrey Nathan Schirripa | Cannabinoid Compositions and Methods |
| EP3078374B1 (en) | 2011-10-17 | 2019-06-19 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| US8889707B2 (en) * | 2012-02-08 | 2014-11-18 | Malka COHEN-ARMON | Treatment of addiction |
| US9645151B2 (en) | 2012-08-17 | 2017-05-09 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
| US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
| US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
| US11103180B2 (en) * | 2013-12-20 | 2021-08-31 | Koninklijke Philips N.V. | Advice system structured to identify an appropriate medical device based upon genetic analysis |
| US20160074510A1 (en) * | 2014-09-15 | 2016-03-17 | Frank Murdock | Method and device to deliver antifibrinolytic drugs to impede tumor growth and increase the radio sensitivity of cancerous tissue |
| US11576882B2 (en) | 2014-09-15 | 2023-02-14 | Murdock Technologies, Llc | Method to deliver antifibrinolytic drugs to mitigate damage to the brain caused by concussive impact |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| US11342080B2 (en) * | 2015-08-17 | 2022-05-24 | Siemens Healthcare Gmbh | Method and system for disease progression modeling and therapy optimizing for individual patients |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US20190008961A1 (en) * | 2016-01-07 | 2019-01-10 | The Broad Institute, Inc. | Compounds and methods for increasing tumor infiltration by immune cells |
| US10792232B2 (en) | 2016-10-19 | 2020-10-06 | Murdock Technologies, Llc | Methods to deliver antifibrinolytic drugs for anti-aging results |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| US11229657B2 (en) | 2017-04-21 | 2022-01-25 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
| RU2019142102A (ru) | 2017-05-19 | 2021-06-21 | Лунелла Байотек, Инк. | Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| US11433074B2 (en) | 2017-06-22 | 2022-09-06 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| US20200113852A1 (en) * | 2017-06-22 | 2020-04-16 | Triact Therapeutics, Inc. | Methods of patient selection and treating trxr- or prdx-overexpressed cancers |
| MX2019014806A (es) | 2017-06-26 | 2020-02-10 | Lunella Biotech Inc | Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas. |
| WO2019067991A1 (en) | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND USES THEREOF |
| IL312038A (en) * | 2017-11-02 | 2024-06-01 | Genmab As | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| EP3765613A1 (en) | 2018-03-13 | 2021-01-20 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| IL278522B2 (en) | 2018-05-07 | 2025-10-01 | Genmab As | Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TWI874453B (zh) * | 2020-09-17 | 2025-03-01 | 日商細胞雲股份有限公司 | 使用末稍血循環腫瘤細胞之解析的癌症治療方法 |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2669583A (en) * | 1954-02-16 | X-amroo-zralkoxbbenzamdjes | ||
| US2006735A (en) * | 1932-11-17 | 1935-07-02 | Gen Aniline Works Inc | Nitro-aryl amino-aryl amines |
| NL247377A (ru) * | 1957-11-25 | |||
| US3161564A (en) | 1960-10-03 | 1964-12-15 | Salsbury S Lab Dr | Veterinary composition containing halo-nitro-benzamides and methods of using same |
| BE637389A (ru) * | 1962-09-13 | |||
| GB1013907A (en) | 1962-09-13 | 1965-12-22 | Ici Ltd | Alkene derivatives |
| US3228833A (en) * | 1962-12-17 | 1966-01-11 | Sterling Drug Inc | Anticoccidial compositions and methods of using same |
| AR204004A1 (es) | 1973-04-02 | 1975-11-12 | Lilly Co Eli | Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina |
| FR2456731A1 (fr) | 1979-05-16 | 1980-12-12 | Choay Sa | Nouveaux derives substitues d'ary |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS6019790A (ja) * | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5041653A (en) * | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
| US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| JP2534631B2 (ja) * | 1986-01-17 | 1996-09-18 | プリベンティブ メディシン インスティテュート | Ｄｎａが関連する病気にかかり易い体質または該病気に対する感受性を測定するための試験 |
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US4923885A (en) * | 1988-08-19 | 1990-05-08 | Merck & Co., Inc. | 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents |
| US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| JPH05503073A (ja) | 1989-09-26 | 1993-05-27 | オクタマー，インコーポレイテッド | ウイルス性疾患の治療に有用な６―アミノ―１，２―ベンゾピロン |
| US5719151A (en) * | 1990-05-04 | 1998-02-17 | Shall; Sydney | Substituted benzene compounds |
| US5633282A (en) | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
| US5232735A (en) | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
| US5631038A (en) | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5637618A (en) | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
| ATE186461T1 (de) * | 1990-09-28 | 1999-11-15 | Smithkline Beecham Corp | Verfahren zur herstellung wasserlöslicher camptothecinanaloge, sowie die verbindungen 10- hydroxy-11-c(1-6)-alkoxycamptothecin |
| US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
| US5243050A (en) * | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5162532A (en) * | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5247089A (en) * | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| EP0533902A1 (en) | 1991-04-10 | 1993-03-31 | Octamer, Inc. | A method for inhibition of retroviral replication |
| US5482975A (en) | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
| US5516941A (en) | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
| US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
| US5753674A (en) | 1991-10-22 | 1998-05-19 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents |
| US5877185A (en) | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| US5473074A (en) | 1991-10-22 | 1995-12-05 | Octamer, Incorporated | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54 |
| US5262564A (en) * | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| US5783599A (en) * | 1993-02-24 | 1998-07-21 | Octamer Inc | Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones |
| DZ1781A1 (fr) | 1993-05-21 | 2002-02-17 | Radopah Ltd | Agents d'arylation. |
| JP3025602B2 (ja) * | 1993-05-21 | 2000-03-27 | デビオファーム エス．アー． | 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法 |
| US6015792A (en) | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US6008250A (en) | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JP3154399B2 (ja) * | 1996-07-04 | 2001-04-09 | デビオファーム エス．アー． | 白金化合物の製造方法 |
| TR199800127T1 (xx) | 1995-08-02 | 1998-04-21 | Newcastle University Ventures Limited | Benzimidazol bile�ikleri. |
| GB9615619D0 (en) | 1996-03-18 | 1996-09-04 | Radopath Ltd | Costimulation of TcR/CD3-induced T-Lymphocytes |
| US5837729A (en) | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
| IL132029A0 (en) * | 1997-03-26 | 2001-03-19 | Biosource Tech Inc | Pharmaceutical compositions containing di-aryl ethers |
| AU7074298A (en) | 1997-04-10 | 1998-10-30 | Foster, Robert T. | Activated iododerivatives for the treatment of cancer and aids |
| US5908861A (en) | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
| US6426415B1 (en) * | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
| US6235748B1 (en) * | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6121278A (en) * | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6514983B1 (en) * | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US5922775A (en) * | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
| US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
| US6380193B1 (en) * | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| JP2002515488A (ja) * | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法 |
| CO5070700A1 (es) | 1998-06-05 | 2001-08-28 | Basf Ag | Genes novedosos de (adp-ribosa) polimerasa |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| ES2216625T3 (es) * | 1998-11-27 | 2004-10-16 | ABBOTT GMBH & CO. KG | Bencimidazoles substituidos y su empleo como inhibidores de parp. |
| US6326517B1 (en) | 1998-12-10 | 2001-12-04 | Central Glass Company, Limited | Method of producing benzamides |
| JP3552934B2 (ja) | 1998-12-24 | 2004-08-11 | セントラル硝子株式会社 | 安息香酸アミド類の製造方法 |
| US6387902B1 (en) * | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
| US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| SK287338B6 (sk) | 1999-01-11 | 2010-07-07 | Agouron Pharmaceuticals, Inc. | Tricyklická zlúčenina, jej použitie a farmaceutická kompozícia s jej obsahom |
| US6677333B1 (en) * | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
| US6423696B1 (en) * | 1999-04-16 | 2002-07-23 | The United States Of America, As Represented By The Department Of Health & Human Services | Inhibition of arylamine N-acetyl transferase |
| DE19921567A1 (de) * | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| GB9915995D0 (en) | 1999-07-09 | 1999-09-08 | Ahmed S | Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors |
| ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US6803457B1 (en) * | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6277990B1 (en) * | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
| US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| WO2001090077A1 (en) * | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| ITMI20002358A1 (it) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| DE10064423A1 (de) | 2000-12-21 | 2002-07-04 | Symyx Technologies Inc | Verfahren zur Herstellung substituierter organischer Verbindungen und Verwendung von Katalysatoren für Substitutionsreaktionen |
| JPWO2002055076A1 (ja) | 2001-01-04 | 2004-05-13 | 第一製薬株式会社 | シクロデキストリン製剤 |
| US20020142334A1 (en) * | 2001-01-30 | 2002-10-03 | Brown Janice A. | Methods of detecting poly(ADP-ribose) polymerase enzymatic activity |
| US20020164633A1 (en) | 2001-04-20 | 2002-11-07 | Inotek Pharmaceuticals Corporation | Cell-based assay for detecting activation of poly (ADP-ribose) polymerase |
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| AU2002331621B2 (en) * | 2001-08-15 | 2008-06-05 | Icos Corporation | 2H-phthalazin-1-ones and methods for use thereof |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| BR0215650A (pt) * | 2002-03-26 | 2005-01-04 | Banyu Pharma Co Ltd | Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica |
| AU2003220935A1 (en) | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
| US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Protein stabilized liposomal formulations of pharmaceutical active ingredients |
| EP1611137A1 (en) | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ES2527871T3 (es) * | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
| EP1633362B1 (en) * | 2003-05-28 | 2012-09-26 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
| US20050004038A1 (en) * | 2003-06-27 | 2005-01-06 | Lyon Robert P. | Bivalent inhibitors of Glutathione-S-Transferases |
| NZ544989A (en) * | 2003-07-25 | 2009-10-30 | Cancer Rec Tech Ltd | Tricyclic PARP inhibitors |
| RU2006106267A (ru) * | 2003-08-01 | 2006-07-27 | Уайт Холдингз Корпорейшн (Us) | Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака |
| BRPI0414136A (pt) * | 2003-09-04 | 2006-10-31 | Aventis Pharma Inc | indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp) |
| WO2005023765A1 (en) | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
| BRPI0416817A (pt) | 2003-11-20 | 2007-03-06 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase |
| AU2004295058B9 (en) | 2003-11-20 | 2011-06-30 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| BRPI0417056A (pt) * | 2003-12-01 | 2007-02-06 | Kudos Pharm Ltd | inibidores de reparo de dano no dna para tratamento de cáncer |
| AU2004295059B2 (en) | 2003-12-05 | 2010-12-16 | Janssen Pharmaceutica N.V. | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| US7652014B2 (en) | 2003-12-10 | 2010-01-26 | Janssen Pharmaceutica | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| US7439031B2 (en) * | 2003-12-15 | 2008-10-21 | The Trustees Of The University Of Pennsylvania | Method of identifying compounds that induce cell death by necrosis |
| US7680864B2 (en) | 2004-03-02 | 2010-03-16 | Intel Corporation | Method and apparatus for managing access to stored objects based on retention policy |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| JP2005336083A (ja) | 2004-05-26 | 2005-12-08 | Sumitomo Chemical Co Ltd | 芳香族アミノ化合物の製造方法 |
| BRPI0512790A (pt) | 2004-06-30 | 2008-04-08 | Janssen Pharmaceutica Nv | derivados de 2-alquil quinazolinona substituìdos como inibidores de parp |
| NZ551799A (en) | 2004-06-30 | 2009-11-27 | Janssen Pharmaceutica Nv | Phthalazine derivatives as PARP inhibitors |
| WO2006003148A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
| US20060035890A1 (en) | 2004-08-10 | 2006-02-16 | Amit Banerjee | Compounds and methods for the treatment of ubiquitin conjugating disorders |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| MX2007002461A (es) * | 2004-09-22 | 2008-03-13 | Pfizer | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona. |
| MX2007003314A (es) | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| PE20060600A1 (es) | 2004-10-29 | 2006-07-14 | Banyu Pharma Co Ltd | Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa |
| US20060094676A1 (en) * | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| CN1768732A (zh) | 2004-11-02 | 2006-05-10 | 上海富海科申药业有限公司 | 芳香硝基化合物在制备治疗肿瘤药物中的应用 |
| CN1768733A (zh) | 2004-11-02 | 2006-05-10 | 上海富海科申药业有限公司 | 芳香硝基化合物在制备治疗艾滋病药物中的应用 |
| DE102005023834A1 (de) | 2004-11-20 | 2006-05-24 | Bayer Healthcare Ag | Substituierte[(Phenylethanoyl)amino]benzamide |
| GB0428111D0 (en) | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
| JP2008526237A (ja) * | 2005-01-07 | 2008-07-24 | アーキュル， インコーポレイテッド | Ｐａｒｐの調節のための組成物およびそのスクリーニング方法 |
| WO2006110683A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| BRPI0611814A2 (pt) * | 2005-06-10 | 2008-12-09 | Bipar Sciences Inc | moduladores parp e tratamento de cÂnceres |
| NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
| CN101370497B (zh) | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | 包含parp抑制剂和细胞毒性剂的联合产品及用途 |
| US20080293795A1 (en) | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
| AU2007228984B2 (en) | 2006-03-22 | 2012-05-03 | Syncore Biotechnology Co., Ltd | Treatment of triple receptor negative breast cancer |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20070292883A1 (en) | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| DE102006037399A1 (de) * | 2006-08-10 | 2008-02-14 | Archimica Gmbh | Verfahren zur Herstellung von Arylaminen |
| EP2061479A4 (en) * | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
| US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| US20080076778A1 (en) | 2006-09-05 | 2008-03-27 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| CN101190211B (zh) | 2006-11-23 | 2011-08-10 | 上海富海科申药业有限公司 | 芳香硝基化合物在制备治疗病毒性肝炎药物中的应用 |
| EP2805945B1 (en) * | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| HRP20120960T1 (hr) | 2007-01-16 | 2012-12-31 | Bipar Sciences, Inc. | Formulacije za lijeäśenje raka |
| DK2134691T3 (da) | 2007-03-08 | 2012-05-07 | Janssen Pharmaceutica Nv | Quinolinonderivativer som parp- og tank-inhibitorer |
| CN101903025A (zh) * | 2007-10-19 | 2010-12-01 | 彼帕科学公司 | 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物 |
| CA2705537A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20090149397A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| CA2713156A1 (en) | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| MX2011008221A (es) | 2009-02-04 | 2011-08-17 | Bipar Sciences Inc | Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno. |
-
2006
- 2006-07-18 NZ NZ587586A patent/NZ587586A/en not_active IP Right Cessation
- 2006-07-18 EP EP06787758A patent/EP1906948A4/en not_active Withdrawn
- 2006-07-18 KR KR1020137004016A patent/KR20130028149A/ko not_active Withdrawn
- 2006-07-18 CN CN2006800305836A patent/CN101242822B/zh not_active Withdrawn - After Issue
- 2006-07-18 JP JP2008522904A patent/JP5177429B2/ja active Active
- 2006-07-18 SG SG201005198-5A patent/SG164368A1/en unknown
- 2006-07-18 CN CN2011102015760A patent/CN102335163A/zh active Pending
- 2006-07-18 KR KR1020087003593A patent/KR20080035630A/ko not_active Withdrawn
- 2006-07-18 RU RU2008105663/15A patent/RU2447889C2/ru not_active IP Right Cessation
- 2006-07-18 NZ NZ565654A patent/NZ565654A/en not_active IP Right Cessation
- 2006-07-18 ZA ZA200800907A patent/ZA200800907B/xx unknown
- 2006-07-18 US US11/458,379 patent/US7405227B2/en not_active Expired - Fee Related
- 2006-07-18 CA CA002615374A patent/CA2615374A1/en not_active Withdrawn
- 2006-07-18 BR BRPI0613783-0A patent/BRPI0613783A2/pt not_active Application Discontinuation
- 2006-07-18 WO PCT/US2006/027907 patent/WO2007011962A2/en not_active Ceased
-
2008
- 2008-01-13 IL IL188746A patent/IL188746A0/en unknown
- 2008-02-13 NO NO20080785A patent/NO20080785L/no unknown
- 2008-06-30 US US12/165,437 patent/US8377985B2/en not_active Expired - Fee Related
-
2011
- 2011-12-22 RU RU2011152491/15A patent/RU2011152491A/ru unknown
-
2012
- 2012-09-05 JP JP2012195125A patent/JP2013006860A/ja not_active Withdrawn
- 2012-11-29 US US13/689,451 patent/US20130331457A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465987B2 (en) | 2010-03-01 | 2022-10-11 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| US12187720B2 (en) | 2010-03-01 | 2025-01-07 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| RU2762111C1 (ru) * | 2010-08-24 | 2021-12-15 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Соединения для лечения рака |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20080785L (no) | 2008-04-15 |
| US7405227B2 (en) | 2008-07-29 |
| HK1120441A1 (en) | 2009-04-03 |
| JP2009501799A (ja) | 2009-01-22 |
| US20130331457A1 (en) | 2013-12-12 |
| US20070015837A1 (en) | 2007-01-18 |
| WO2007011962A2 (en) | 2007-01-25 |
| SG164368A1 (en) | 2010-09-29 |
| KR20130028149A (ko) | 2013-03-18 |
| EP1906948A4 (en) | 2010-03-17 |
| CN102335163A (zh) | 2012-02-01 |
| US8377985B2 (en) | 2013-02-19 |
| CN101242822A (zh) | 2008-08-13 |
| IL188746A0 (en) | 2008-08-07 |
| CN101242822B (zh) | 2011-08-24 |
| BRPI0613783A2 (pt) | 2011-02-01 |
| AU2006269934A1 (en) | 2007-01-25 |
| KR20080035630A (ko) | 2008-04-23 |
| WO2007011962A3 (en) | 2007-12-13 |
| CA2615374A1 (en) | 2007-01-25 |
| RU2011152491A (ru) | 2013-06-27 |
| ZA200800907B (en) | 2010-04-28 |
| RU2447889C2 (ru) | 2012-04-20 |
| JP2013006860A (ja) | 2013-01-10 |
| JP5177429B2 (ja) | 2013-04-03 |
| NZ565654A (en) | 2010-10-29 |
| EP1906948A2 (en) | 2008-04-09 |
| US20080319054A1 (en) | 2008-12-25 |
| NZ587586A (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008105663A (ru) | Способ лечения рака (варианты) | |
| RU2009110480A (ru) | Фторсодержащие лиганды для нацеливания периферических бензодиазепиновых рецепторов | |
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| CA2662517A1 (en) | Treatment of cancer | |
| RU2008122046A (ru) | Аминопиримидины в качестве ингибиторов киназ | |
| HRP20160625T1 (hr) | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka | |
| JP2010539095A5 (ru) | ||
| JP2007511504A5 (ru) | ||
| JP2019516766A5 (ru) | ||
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
| JP2011520770A5 (ru) | ||
| RU2010108448A (ru) | Способы индукции конечной дифференцировки | |
| JP2010501572A5 (ru) | ||
| AR088643A1 (es) | Compuestos de 8-fluoroftalazin-1(2h)-ona | |
| BRPI0408876A (pt) | derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| AR121299A1 (es) | Inhibidores heterocíclicos de pad4 | |
| AR065599A1 (es) | Benzotiofenos y benzofuranos 2- heteroarilo sustituidos | |
| RU2009124622A (ru) | Новые гидрофильные производные 2-арил-4-хинолонов в качестве противораковых агентов | |
| PE20161240A1 (es) | Agentes anticancerosos y sus preparaciones | |
| JP2009503110A5 (ru) | ||
| JP2013511526A5 (ru) | ||
| JP2019527740A5 (ru) | ||
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MZ4A | Patent is void |
Effective date: 20131205 |